Previous 10 | Next 10 |
home / stock / imexf / imexf news
Imagin Medical (OTCQB:IMEXF) closes a new convertible note offering totaling $3M in three tranches by Rapha Capital BioVentures Fund I, LP (RCBVFI) to support the clinical development of product, the i/Blue™ Imaging System. The principal and interest will automatically conver...
Rapha Capital BioVentures Fund I, LP (RCBVFI) leads new convertible note financing. Kevin Slawin, M.D., a leading urooncologist and manager of RCBVFI, joins the board. Imagin Medical’s i/Blue™ Imaging System is poised to increase patient access to ...
A study that was recently published in the “International Journal of Urological Nursing” found that intravesical therapy affected the physical, emotional and social well-being of patients who suffered from non-muscle invasive bladder cancer . The participants of the study un...
Imagin Medical (CSE: IME) (OTCQB: IMEXF) , a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final design of its i/Blue Imaging System(TM) is on target to be demonstrated at the Amer...
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reports that the final design of the i/Blue Ima...
Researchers from the Uppsala University have developed a new mouse model that can be used to study the factors that contribute to the progression of immune-system activation and bladder cancer in humans as the tumor grows. Through this model, the researchers have learned how proteins chang...
Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. The patented technology, which has entered the manufacturing stag...
Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”) Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022 Blue light cystoscopy h...
A new study conducted by researchers from the Memorial Sloan Kettering Cancer Center has discovered that after undergoing bladder removal operations, the risk of high-grade bladder cancer recurrence decreased after the nivolumab formulation was administered to patients. Together with a...
Cancer metastasis is every patient and doctor’s nightmare when it comes to treating this deadly disease. Chemotherapy is usually the primary treatment option, with doctors following up with surgeries to remove any tumors. However, patients suffering from muscle-invasive bladder cance...
News, Short Squeeze, Breakout and More Instantly...
Imagin Medical Inc Company Name:
IMEXF Stock Symbol:
OTCMKTS Market:
2024-03-27 17:08:02 ET Surgical imaging for bladder cancer Imagin Medical is a surgical imaging company. They're focusing on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initially focused on bladder ca...
Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin PR Newswire Ponce Therapeutic's (" Ponce ") lead product, ReBea...
Imagin Medical Announces Stock Option Grants PR Newswire VANCOUVER , BC and BOSTON , April 22, 2022 /PRNewswire/ -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) ( Frankfurt & Stuttgart Symbol: DPD2) ("Imagin" or the "Company") today...